# Titan Biotech share price (Titan Biotech Ltd, NSE: TITANBIO)

> Titan Biotech share price: ₹399.35 at the NSE close on 18 August 2026, the latest close in our records; up 323.8% in the year to that date. Titan Biotech (NSE: TITANBIO) is worth ₹1,650 crore, trades at a P/E of 48.7 and has closed between ₹89.19 and ₹504.00 over the past 52 weeks. > Titan Biotech Ltd's share price has risen faster than its earnings: +323.8% in a year, against +38.8% for earnings per share. TITANBIO · Pesticides/Agrochemicals · data as of 18 August 2026. Page: https://www.sectoralpha.in/stocks/titan-biotech-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹399.35 (+323.8% in a year)
- P/E: 48.7× (higher than 96% of the last 9.9 years)
- Revenue (Jun 2026): ₹59.0 Cr (+28.3% on a year ago)
- Profit (Jun 2026): ₹11.0 Cr (+57.1% on a year ago)
- Operating margin: 21.0% (+2.0 points on a year ago)
- ROCE: 23%, FY26
- Profit that came in as cash: 92%, last 3 years

The main question: the share price moved +323.8% in a year while yearly earnings per share moved +38.8%. The difference came from the market paying a higher multiple. ## What is the Titan Biotech share price? Titan Biotech Ltd's share price was ₹399.35 at the close on 18 August 2026. It has been rising for 49 weeks. That is 15.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹89 and ₹504, and at that close it sat 75% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 13 weeks in a row. Over the last 10 years the share price moved +5,162% while the NIFTY 500 moved +277%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Titan Biotech this quarter? Three changes stood out: best operating margin in 10 quarters, highest quarterly profit in 15 quarters and revenue up on a year earlier for 5 quarters in a row. 1. Best operating margin in 10 quarters Operating margin was 21% in the June 2026 quarter, against 19% a year earlier. 2. Highest quarterly profit in 15 quarters Profit of ₹11 crore in the June 2026 quarter is the highest of the last 15 quarters. 3. Revenue up on a year earlier for 5 quarters in a row In the June 2026 quarter revenue was ₹59 crore, +28.3% on a year earlier. ## What are Titan Biotech's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Titan Biotech reported revenue of ₹59.0 crore, up 28.3% from ₹46.0 crore a year earlier, and a profit of ₹11.0 crore, up 57.1% from ₹7.00 crore. ### Titan Biotech results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹59.0 crore | ₹46.0 crore | +28.3% |
| Profit | ₹11.0 crore | ₹7.00 crore | +57.1% |
| Earnings per share | ₹2.63 | ₹1.66 | +58.4% |
| Operating margin | 21.0% | 19.0% | +2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Titan Biotech share price history? Titan Biotech closed at ₹399.35 on 18 August 2026, up 323.8% from ₹94.22 a year earlier (14 August 2025) and up 497.8% over five years. Its highest weekly close since March 2016 was ₹424.85 on 17 July 2026. ### Titan Biotech share price: then and now

| When | Close | Change to 18 Aug 2026 |
| --- | --- | --- |
| 1 week ago · 14 Aug 2026 | ₹411.10 | −2.9% |
| 1 month ago · 17 Jul 2026 | ₹424.85 | −6.0% |
| 6 months ago · 20 Feb 2026 | ₹297.75 | +34.1% |
| 1 year ago · 14 Aug 2025 | ₹94.22 | +323.8% |
| 3 years ago · 18 Aug 2023 | ₹75.37 | +429.9% |
| 5 years ago · 20 Aug 2021 | ₹66.80 | +497.8% |
| 10 years ago · 16 Aug 2016 | ₹7.22 | +5,431.2% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹7.59 | +5,161.5% |
| Highest weekly close since March 2016 · 17 Jul 2026 | ₹424.85 | −6.0% |
| Lowest weekly close since March 2016 · 30 Aug 2019 | ₹6.40 | +6,139.8% |
| 52-week high (weekly close) · 2 Apr 2026 | ₹504.00 | −20.8% |
| 52-week low (weekly close) · 22 Aug 2025 | ₹89.19 | +347.8% |

Weekly closing prices. Each change is the move from that price to the 18 Aug 2026 close. A day's intraday high or low can go beyond these weekly closes. (530 weekly closes from 11 March 2016 to 18 August 2026.)

## What is the latest news on Titan Biotech? 18 Aug 2026: Titan Biotech closed at ₹399.35, down 2.9% on the week and down 6.0% on the month. Results for April to June 2026: Revenue up 28.3% and profit up 57.1% on a year earlier. ## What dividend does Titan Biotech pay? The NSE corporate-actions record has no dividend for Titan Biotech since 1 April 2021, so this page cannot show amounts per share. Yes. Titan Biotech Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 12 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Titan Biotech on? Titan Biotech is not on any of our India lists this week. ## Is Titan Biotech profitable? Titan Biotech Ltd earned ₹11.0 Cr of net profit in the Jun 2026 quarter, +57.1% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹30.0 Cr. Over 10 years profit has grown 31.1% a year on average. That is 18.6% of the quarter's revenue. The same quarter a year earlier earned ₹7.0 Cr. For the full year, FY26 profit was ₹30.0 Cr (+36.4% on the year before). Why profit moved: revenue changed +28.3% on a year earlier and the margin moved +2.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +67.9% and revenue +38.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Titan Biotech make, and is it growing? Titan Biotech Ltd reported ₹59.0 Cr of revenue in the Jun 2026 quarter, +28.3% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 10 years it has grown 16.2% a year on average. The last full year, FY26, came in at ₹206 Cr. The last four reported quarters add to ₹219 Cr. FY26 revenue was ₹206 Cr, +32.1% on the year before. Recent pace: the last four quarters grew +38.3% on average, against 16.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +37.7%, against +12.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +59.1%, against +18.3% a year (accelerating). ## How much of every ₹100 of sales does Titan Biotech keep? Titan Biotech Ltd's operating margin was 21.0% in the Jun 2026 quarter, 2.0 percentage points higher than the same quarter a year ago. Across 12 years it has been between 9.0% and 32.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.3 percentage points on the year while gross margin changed +4.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Titan Biotech's profit turning into cash? Over the last 3 years, 92% of Titan Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹30.0 Cr of operating cash against ₹30.0 Cr of profit. After ₹10.0 Cr of spending on assets, ₹20.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 92% of profit came in as cash: the cash cycle got 17 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building. ## Where does Titan Biotech's cash go? Titan Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 220 days in FY26, up from 203 days in FY21. It spent ₹27.0 Cr on assets over the last 3 years. Customers take 40 days to pay, and stock sits for 212 days on average. At FY26 sales of ₹206 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly ₹124 Cr is tied up in the business at any time. FY26: customers took 40 days to pay and stock sat for 212 days, about 7.0 months of sales sitting as stock, for a full cycle of 220 days, longer than FY21's 203. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 212 days. Customers pay about 40 days after that. Suppliers are paid at 32 days. Together that makes the 220-day cycle. Spending on assets: ₹27.0 Cr over the last 3 years, against ₹12.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹2.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Titan Biotech's P/E ratio, and how does it compare with its own history? Titan Biotech Ltd's P/E is 48.7×, near the high end of its own history: higher than 96% of past readings. Its usual P/E (the middle reading) is 12.6×, over 9.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +38.8% while the price moved +323.8%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +43.0% a year; about +5.0% a year came from earnings growth and about +38.0 percentage points from the multiple (the market paying more); over 10 years the price moved +49.4% a year; about +33.4% a year came from earnings growth and about +16.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Titan Biotech share price assume? Worked out from its price on 13 June 2026, Titan Biotech Ltd's share price assumed profit growth of about 23.9% a year. Over the past 10 years its profit actually grew 31.1% a year. Today its P/E is 48.7×, higher than 96% of its own last 9.9 years. This is a one-day reading, taken on 13 June 2026. Every other number on this page, the multiple included, uses the latest price as of 18 August 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Titan Biotech business getting better or worse? Titan Biotech Ltd's business is turning around. Profit growth has swung from −12.0% at its low to +59.1%, improving for 4 quarters in a row, with ROCE steady at 23.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Titan Biotech earn on its capital? Titan Biotech Ltd earned a ROCE of 23% in FY26. That is up from a low of 12% in FY16. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 14.6% net margin and 0.96× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 14.6% net margin × 0.96× asset turnover × 1.18× leverage (assets divided by equity) ≈ 16.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Titan Biotech have too much debt? Titan Biotech Ltd had ₹6.0 Cr of borrowings against ₹181 Cr of equity in FY26, so its debt is 0.03× its equity. Its operating profit is 39 times its interest bill. Over 5 years borrowings went from ₹16.0 Cr to ₹6.0 Cr. Over the last 3 of those years it spent ₹27.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Titan Biotech shareholding pattern? No group of Titan Biotech Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.0 points over the same period, to 0.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −0.1 points over 8 quarters, to 55.8%; Domestic institutions: +0.0 points over 8 quarters, to 0.0%. ## How far is Titan Biotech from balance-sheet trouble? For Titan Biotech Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Titan Biotech rank in its industry? There is no score against its industry: Titan Biotech Ltd is not present in the sector comparison for Pesticides/Agrochemicals. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Titan Biotech compared with? No sector comparison is shown here, not present in the sector comparison. ## Which companies are close to Titan Biotech in size? Titan Biotech is the 13th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: NACL Industries, Bhagiradha Chemicals & Industries and GSP Crop Science. Just below it: Bharat Rasayan, Insecticides India and Meghmani Organics. ### Pesticides/Agrochemicals companies close in size

1. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) ₹2,589 crore
2. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) ₹2,533 crore
3. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) ₹2,014 crore
4. Titan Biotech Ltd ₹1,755 crore
5. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) ₹1,557 crore
6. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) ₹1,511 crore
7. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) ₹1,339 crore

[All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies)

### Companies close in size in other industries

1. [Khazanchi Jewellers Ltd](https://www.sectoralpha.in/stocks/khazanchi-jewellers-ltd) ₹1,786 crore · Diamond, Gems & Jewellery
2. [Honda India Power Products Ltd](https://www.sectoralpha.in/stocks/honda-india-power-products-ltd) ₹1,777 crore · Capital Goods - Electric General
3. Titan Biotech Ltd ₹1,755 crore
4. [NINtec Systems Ltd](https://www.sectoralpha.in/stocks/nintec-systems-ltd) ₹1,745 crore · IT - Software
5. [Nitco Ltd](https://www.sectoralpha.in/stocks/nitco-ltd) ₹1,741 crore · Ceramics/Tiles/Sanitaryware

## What else do people ask about Titan Biotech? ### What is Titan Biotech's share price? Titan Biotech Ltd's share price is ₹399.35, +323.8% over the past year. The whole company is worth ₹1,650 Cr on the market. In the last 52 weeks it traded between ₹89 to ₹504; today it is 75% of the way up from the low, 15.8% above its 200-day average (as of 18 August 2026). ### What were Titan Biotech's latest quarterly results? Titan Biotech Ltd reported revenue of ₹59.0 Cr and net profit of ₹11.0 Cr for the Jun 2026 quarter. Revenue rose 28.3% and profit rose 57.1% compared with a year earlier. Earnings per share were ₹2.63. The operating margin was 21.0%, 2.0 percentage points higher than a year earlier (as of 18 August 2026). ### What is Titan Biotech's market cap? Titan Biotech Ltd's market capitalisation is ₹1,650 Cr at a share price of ₹399.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 August 2026). ### How is Titan Biotech performing? Titan Biotech Ltd's share price has been rising for 49 weeks. In its latest quarter, revenue rose 28.3% and profit rose 57.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 13 weeks running (as of 18 August 2026). ### Will Titan Biotech's share price go up? This page does not forecast Titan Biotech Ltd's share price. What it shows instead: the share price is ₹399.35, and it has been rising for 49 weeks. Its P/E of 48.7× is higher than 96% of its own last 10 years (as of 18 August 2026). ### Who owns Titan Biotech? Promoters own 55.8% of Titan Biotech Ltd, foreign institutions , domestic institutions 0.0% and the public 44.2% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 August 2026). ### Where is Titan Biotech in its business cycle? Titan Biotech Ltd's FY26 operating margin was 19.0%, against a 12-year range of 9.0% to 32.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 21.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 August 2026). ### What could break the Titan Biotech story? The main question: the share price moved +323.8% in a year while yearly earnings per share moved +38.8%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 August 2026). ### Is Titan Biotech a stock worth studying right now? What the numbers show: Titan Biotech Ltd's share price has risen faster than its earnings: +323.8% in a year, against +38.8% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 August 2026). This is research, not advice. We’re not SEBI-registered.